Eos SENOLYTIX
Houston, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into Eos SENOLYTIX
116 people in our graph share verified history with the Eos SENOLYTIX team — schools, employers, funds. One of them is your warm intro.
Scott Billerunlockedknows Kevin M. Slawin · together at Columbia University (overlapped)
knows the team · via Bellicum Pharmaceuticals, Inc.
×2knows the team · via Columbia University
×5knows the team · via Baylor College of Medicine
×2knows the team · via Columbia University Vagelos College of Physicians and Surgeons
knows the team · via Memorial Hermann Healthcare System
Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
Founders & leadership
Eos SENOLYTIX was founded in 2024 by Kevin Slawin, M.D..
KS
Kevin Slawin, M.D.in𝕏Founder and CEODr. Kevin Slawin is founder and CEO of Eos SENOLYTIX, a longevity company developing senolytic peptides for age-related conditions. He previously co-founded Bellicum Pharmaceuticals, which went public in 2014, and holds multiple patents in prostate cancer diagnostics and immunotherapy technologies.
KM
Kevin Mark Slawinin𝕏ExecutiveKevin Mark Slawin is a physician and biotech entrepreneur who co-founded Bellicum Pharmaceuticals, which conducted an IPO in 2014, and has since founded multiple longevity and regenerative medicine companies including Eos SENOLYTIX and PrintBio. His background includes work as a robotic surgeon, biotech consultant, and inventor on prostate cancer diagnostic technologies and cell therapy patents.
Board
JW
Jerold WinogradBoard director
FB
Frank Bartlett McGuyerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2026
▶$750KraisedAug 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$750KraisedAug 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin Mark SlawinExecutive Officer, Director
- Frank Bartlett McGuyerDirector
- Jerold WinogradDirector
- Offering amount
- $25M
- Amount sold
- $750K
- Minimum investment
- $250K
- Sales commissions
- $1.4M
- Placement agents
- Floww Private Markets US Inc., Floww Private Markets US Inc., Floww Private Markets US Inc.
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapPhoenix SENOLYTIX4 shared keywordsPhoenix SENOLYTIX develops gene therapies targeting senescent cells to address aging-related conditions. The company utilizes its ApoptiCIDe-CE™ platform technology, validated in human patients, to eliminate unwanted cells in the body.
Cenegenics3 shared keywordsCenegenics is a physician-led age management and performance health system that uses diagnostics and data-driven interventions to help individuals optimize strength, cognition, metabolic health, and longevity. The company serves individuals seeking personalized, medically grounded approaches to extending peak physical and cognitive performance.
Companies competing with Eos SENOLYTIX for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq - TipRanks.comtipranks.com · Mar 2026Frequently asked questions
- What does Eos SENOLYTIX do?
- Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
- Who founded Eos SENOLYTIX?
- Eos SENOLYTIX was founded by Kevin Slawin, M.D. in 2024.
- Who are Eos SENOLYTIX's investors?
- Eos SENOLYTIX's investors include Rapha Capital Management, LLC.
- How much funding has Eos SENOLYTIX raised?
- Eos SENOLYTIX has disclosed $750K raised across 1 round.
- Where is Eos SENOLYTIX headquartered?
- Eos SENOLYTIX is headquartered in Houston, US.